LentiBlast Premium Transduction Enhancer

LentiBlast Premium Transduction Enhancer

Catalog Number:
TR02108533OZB
Mfr. No.:
LBPX500; LBPX1500
Price:
$448
Size:
Quantity:
Add to Cart:
    • Overview
      • LentiBlast Premium is a novelpatented chemical composition that dramatically increases lentiviral infection and transduction efficiency in any type of cells, adherent or in suspension, primary or cell lines. The properties of this reagent allow simultaneously neutralizing electrostatic repulsions between membrane and viral particles and enhancing viral fusion with cell membrane. Due to a favorable “membrane permeable effect” limiting the transmembrane potential changes, LentiBlastPremium is non-toxic and totally compatible with cell viability.
        LentiBlastPremiumTransduction Enhancerovercomes obstacles that prevent successful transduction (cell density, passage number, lentivirus purity, MOI, ...) and allows you to complete efficient transduction efficiencies without Polybrene.
        LentiBlast Premium Transduction Enhancer benefits:
        Increase lentivirus infection efficiency for hard-to-transduce cells: The right solution for Stem cells, Primary T cells
        Save effort & money: Achieve same transduction results with a lower viral titer
        Maximize Cell Viability: Non-toxic

        Sizes :
        500 µL: For up to 100 transductions in a 24-well plate.
        1500 µL: For up to 300 transductions in a 24-well plate.

        Please contact us at for specific academic pricing.

    • Properties
      • Categories
        Lentivirus / Retrovirus Transduction Reagent
        Storage
        -20°C
        Shipping
        Room temperature
    • Applications
      • Application
        Lentivirus / Retrovirus Transduction
        Application Description
        RECOMMENDED FOR: Enhancing lentiviral transduction in a wide range of cell types from CD34+ hematopoietic stem cells to primary cells or cell lines such as HT1080 or SH‑SY5Y.
        Perfect for enhancing lentiviral transduction in CD34+ hematopoietic stem cells, T lymphocytes as well as any other cells.
        Ideal to increase R&D, preclinical and clinical transduction protocols for ex-vivo gene therapies and CAR-T cell therapies.